Overview

A Study of Nipocalimab in Healthy Male and Female Participants

Status:
Recruiting
Trial end date:
2022-07-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of nipocalimab following subcutaneous (SC) administration compared with intravenous (IV) administration in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC